IP Library Patent Application 15249827
Patent Application
App. No. 15/249,827

SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/249,827
Abstract

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R 1 does not exist; W is C or N with the proviso that when W is N, R 2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C 1 -C 6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

Claims (4)

1 . A method for treating a mamal infected with the HIV virus comprising administering to said mamal a pharmaceutically acceptable salt of the compound 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, having the following structure:

2 . The method of claim 1 further comprising the administration of a second AIDS treatment agent selected from the group consisting of AIDS antiviral agents, anti-infective agents, immunomodulators, and HIV entry inhibitors.

3 . A pharmaceutical composition comprising a pharmaceutically acceptable salt of the compound 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, having the following structure:

4 . The pharmaceutical composition of claim 3 further comprising a second AIDS treatment agent selected from the group consisting of AIDS antiviral agents, anti-infective agents, immunomodulators, and HIV entry inhibitors.